impact of PRECISE-DAPT and DAPT score on Dual antiplatelet thearpy duration after 2nd generation DES implantation
- 저자
- Ji-Yong Jang
; Hae Won Jung
; Byoung-Kwon Lee
; Dong-Ho Shin
; Jung-Sun Kim
; Sung-Jin Hong
; Chul-Min Ahn
; Byeong-Keuk Kim
; Young-Guk Ko
; Donghoon Choi
; Myeong-Ki Hong
; Kyung Woo Park
; Hyeon-Cheol Gwon
; Hyo-Soo Kim
; Hyuck Moon Kwon
; Yangsoo Jang
- 키워드 (영문)
- drug-eluting stent; risk score; dual antiplatelet duration; therapy duration; stent; randomized controlled trial; population; medicine; ischemia; internal medicine; high ischemic risk; framingham risk score; cardiology
- 발행연도
- 2020-07
- 발행기관
- medline
- 유형
- Article
- 초록
- PURPOSE
Determining the optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is an important clinical issue. We evaluated the effects of ischemia (by DAPT score) and bleeding (by PRECISE-DAPT score), as well as the impact of DAPT duration, on clinical outcomes.
METHODS
From pooled analysis of four randomized clinical trials, 5131 patients undergoing second-generation DES implantation were randomized to short-duration (n = 2575; ≤ 6 months) or standard-duration (n = 2556; ≥ 12 months) DAPT groups. This population was further divided into four subgroups according to PRECISE-DAPT (high bleeding risk ≥ 25) and DAPT (high ischemic risk ≥ 2) scores.
RESULTS
Net clinical outcomes (1.3% vs. 1.3%; p = 0.89) and ischemic events (5.0% vs. 4.5%; p = 0.44) did not differ between the two duration groups, although bleeding events were more frequent in patients with standard-duration DAPT (0.4% vs. 0.9%; p = 0.04). Standard-duration DAPT was associated with fewer ischemic events (6.9% vs. 4.0%; p = 0.02) and no increase in bleeding events only among patients at low bleeding risk and high ischemic risk. The other groups show no differences in net clinical outcomes, ischemic events, or bleeding events according to DAPT duration.
CONCLUSION
Compared with short-duration DAPT, standard-duration DAPT was associated with similar net clinical outcomes and ischemic events, but more bleeding events at 12 months after second-generation DES implantation. However, standard-duration DAPT reduced ischemic events without increasing bleeding events among patients at low bleeding and high ischemic risk. When determining DAPT duration, considering both ischemic and bleeding risk can help optimize patient benefits.
CLINICAL TRIAL REGISTRATION
EXCELLENT (NCT00698607), RESET (NCT01145079), IVUS-XPL (NCT01308281), OPTIMA-C (NCT03056118).
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
참고문헌 22
- 저널명
- CARDIOVASCULAR DRUGS AND THERAPY
- 저널정보
- (2020-07). CARDIOVASCULAR DRUGS AND THERAPY, Vol.35(2), 343–352
- ISSN
- 0920-3206
- EISSN
- 1573-7241
- DOI
- 10.1007/s10557-020-07008-7
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.